MRI and Computational Simulation Cardiology Study
MR Imaging and Computational Simulation of Cardiovascular Physiology Including Velocity, Pressure, and Wall Shear Stress
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Lucile Packard Children's Hospital at Stanford
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients will have congenital heart disease or acquired cardiopulmonary disease.
- normal volunteers will be willing to undergo MRI
Exclusion Criteria:
- patients unable to receive intravenous contrast material (this does not apply to normal volunteers)
- subjects with arrhythmias which will prevent MRI cardiac gating
- subjects with illnesses which make participation inappropriate. In addition, patients who would normally be excluded from an MRI study because of pacemaker implant, aneurysm clip, severe claustrophobia, or any other condition which, based on the Investigator's judgment, would preclude proximity to a strong magnetic field will be excluded from this study as well.
- NORMAL VOLUNTEERS may be excluded if they are not able to remain still during the exam or follow the instructions of the investigators.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Study
Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
|
All subjects will undergo or have already undergone Magnetic Resonance Imaging.
Normal volunteers will be used for comparison with subjects.
To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
|
|
Normal Volunteers
No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
|
All subjects will undergo or have already undergone Magnetic Resonance Imaging.
Normal volunteers will be used for comparison with subjects.
To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wall Shear Stress
Time Frame: 20 years
|
Computational parameters derived from clinical diagnostic modalities
|
20 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jeffrey Feinstein, MD, MPH, Stanford University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SQL 80004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07612657Not yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
NCT07217522RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
-
NCT07172334Not yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
NCT03205085UnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
-
NCT07632898Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07604805RecruitingIdiopathic Pulmonary Hypertension
-
NCT07266519Not yet recruiting
-
NCT02565030CompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension
-
NCT04808596RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary | Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Clinical Trials on Magnetic Resonance Imaging
-
NCT03980535CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
-
NCT02702830CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject
-
NCT00965003TerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx Cancer
-
NCT00474604Completed
-
NCT01018329Completed
-
NCT04563806TerminatedThoracic Spine Neoplasm
-
NCT04876378TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8
-
NCT04047264RecruitingGlioma | Glioblastoma | Metastatic Malignant Neoplasm in the Brain
-
NCT04022746CompletedAdvanced Adult Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8
-
NCT06728592RecruitingStroke | Brain Diseases | Ischemic Stroke | Stroke, Ischemic | Stroke, Acute | Stroke Hemorrhagic | Intracerebral Hemorrhage | Stroke (CVA) or TIA